Dapagliflozin for pulmonary hypertension
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests whether a diabetes medicine called dapagliflozin can help people with pulmonary hypertension. It may improve symptoms and heart function, and the trial will monitor safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pulmonary hypertension, either by a heart test (right heart catheterization) or by an echocardiogram, following ESC guidelines.
- Your blood pressure is not too low (systolic blood pressure at least 95 mmHg).
- Your kidney function is adequate (eGFR at least 30) and your potassium level is not too high (≤ 5.2 mmol/L).
- You do not have significant liver problems, active cancer, or are not currently on hormone therapy, chemotherapy, or immunotherapy.
- You do not have type 1 diabetes, acute pulmonary embolism, significant primary heart valve disease, or ischemic heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
This trial tests a medication called dapagliflozin (often used in type 2 diabetes) to see if it can help protect the kidneys in people with type 1 diabetes who already have some signs of kidney damage. If it works, it could slow down further kidney decline.
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.